What RxGenomix does

RxGenomix is a Tennessee-based pharmacogenomics (PGx) services company founded in 2013 that operates the ExactMeds® program and the proprietary RxGenomix Hub platform. The company's core offering is a 45-gene PGx test (analyzing drug-metabolizing enzymes such as CYP2D6, CYP2C9, CYP2C19, CYP3A4/5, VKORC1, SLCO1B1, etc.) processed via partner CLIA-certified laboratories from a cheek-swab saliva sample, combined with a clinical decision support tool that evaluates medication options against genetics, drug-drug interactions, disease state, lifestyle factors, medication cost, and Beer's list criteria. RxGenomix is positioned explicitly as a services-and-platform company rather than a laboratory, aggregating lab partners, a network of PGx-trained pharmacists, prescribers, and an online portal (hub.rxgenomix.com) that supports ordering, results access, and care coordination.

The business model is multi-stream. One-time revenue comes from individual PGx testing and from CE education courses (including an 8-hour ACPE-accredited course built with CEimpact). Professional-services revenue comes from pharmacist-led clinical consultations documented in Medication Action Plans. Recurring / enterprise revenue comes from organization-wide PGx programs sold to employers, benefits providers, and healthcare organizations, bundled with Population Analytics and practice integration services. Go-to-market combines direct enterprise sales, a pharmacist channel network, prescriber ordering via the Hub, and direct consumer ordering through the website with provider approval required to process tests. Pricing is quote-based and not publicly disclosed, with partial coverage available through some commercial insurance and Medicare for qualifying patients.

The company's strategic and operational footprint remains US-only, headcount is listed at 1-10, and it discloses no institutional funding rounds. Anchor enterprise relationships include a partnership with prescription benefit facilitator BeneCardPBF (announced December 2019) and an integration with precision-medicine technology provider Translational Software (May 2020). Leadership includes CEO Brad Tice (PharmD, MBA), COO Blake Keller (PharmD), SVP of IT Brad Mitchell, and Director of Clinical Pharmacogenomic Operations Dr. Ina Liko (PharmD, MSCS). The company is HIPAA-verified, recognized as a 2023 NEXT Award winner in Middle Tennessee, and its reporting structure flags that genetic health risk information is not FDA-reviewed — consistent with a regulated but non-device clinical service.

Name

RxGenomix

Legal name

RxGenomix, LLC

Website

https://rxgenomix.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

RxGenomix is a Tennessee-based pharmacogenomics services company that analyzes 45 drug-metabolism genes and operates the ExactMeds program and RxGenomix Hub platform to deliver personalized prescribing for individuals, employers, benefit providers, pharmacists, and prescribers.

Ownership category

akta.pro rank

Product category

Pharmacogenomics Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (541690)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Pharmacogenomics (PGx) Decision Support (HLAAANAB)

akta.pro secondary industries

Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF), Healthcare Outcomes & Real-World Evidence (RWE) Analytics (BPAHALAN)

Keywords

• Pharmacogenomics testing
• Personalized medication management
• Clinical decision support
• Pharmacy consultation services
• Genetic drug response

Headquarters

HQ city

Franklin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. PGx Testing Services: One-time pharmacogenomic testing for individuals, ordered by healthcare providers. Saliva sample collected via cheek swab, processed by partner CLIA-certified laboratories. Test results stored for future reference.
2. Clinical Consultation Services: PGx-trained pharmacists provide consultation services to healthcare providers based on test results. Pharmacists earn reimbursement for consultations and can add this as a revenue-generating service line to their practice.
3. Enterprise/Benefit Program Solutions: Population-level PGx programs sold to employers, benefit providers, and healthcare organizations. Includes analytics, testing coordination, pharmacist network access, and ongoing program management.
4. CE Education Courses: Continuing education courses for pharmacists and healthcare providers on pharmacogenomics, including an 8-hour accredited course and free introductory courses.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

RxGenomix operates a pharmacogenomics (PGx) services platform that combines a 45-gene genetic test (cheek swab, processed at partner CLIA-certified labs) with the proprietary RxGenomix Hub — a secure portal providing clinical decision support, population analytics, and pharmacist-led consultations. The company sells ExactMeds® testing programs to individuals (via provider order), to employers and benefit providers (enterprise solutions), and to pharmacists (practice integration), supported by an ACPE-accredited CE training course.

Product overview

RxGenomix is a pharmacogenomics (PGx) services company offering ExactMeds®, a comprehensive and highly scalable approach to personalized medicine. The portfolio includes: the RxGenomix Hub platform (connecting care teams and providing clinical decision support), Individual Testing services (cheek swab-based testing of 45 genes), Enterprise Solutions and Population Analytics (for employers and benefit providers), and Practice Integration services (for pharmacists). The ecosystem is supported by educational offerings including an 8-hour ACPE-accredited CE course and monthly Clinical Pearls webinars. All offerings center on using genetic testing to guide personalized prescribing decisions.

Differentiator

Problem solved

Functional benefit

Brands

• ExactMeds: The pharmacogenomic testing program and brand offering personalized medication therapy based on individual genetics.

Products and services

• ExactMeds® Primary pharmacogenomic testing program and brand that analyzes patient genetics to guide personalized medication selection and dosing, intended to reduce adverse drug events and improve treatment outcomes for individuals, healthcare providers, benefit administrators, and employers.
• RxGenomix Hub Proprietary, secure online portal connecting pharmacists, physicians, nurse practitioners and patients to order tests, access results, deliver clinical decision support, and coordinate personalized medication care.
• Individual Testing Pharmacogenomic testing for individual patients using a cheek swab DNA sample analyzed for 45 genes affecting drug metabolism, with results interpreted by PGx-trained pharmacists and shared with the patient's prescribing provider.
• Enterprise Solutions

Quantifiable outcome

• 29% reduction in hospitalizations and 18% reduction in pharmacy expenses for retiree groups implementing ExactMeds program
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature5 records

Partnerships

Five partnerships are on record, tiered minor and core.

• Base Camp HealthminorStrategic or Co-development Partner · 17 June 2020Partnership for innovative return-to-work solution combining PGx testing with digital daily monitoring. RxGenomix added Base Camp Health's digital monitoring solution to offer comprehensive COVID-19 workplace response capabilities.
• Translational SoftwarecoreTechnology or Integration · 12 May 2020Partnership with Translational Software (TSI), a leader in intelligent use of genetic data for clinical decision support and precision medicine. The partnership increases the value of individual offerings and makes pharmacogenomic services more comprehensive by combining RxGenomix's testing and pharmacist network with TSI's clinical decision support technology.
• BeneCardPBFcoreStrategic or Co-development Partner · 17 December 2019Innovative prescription benefit facilitator that leverages the RxGenomix Hub to deliver personalized medication care for their members. BeneCardPBF strives to bring the best solutions to clients and members, and the RxGenomix integration is part of their leadership in the industry.
• CLIA-certified Laboratory PartnerscoreTechnology or IntegrationRxGenomix partners with clinical testing laboratories accredited by the College of American Pathologists and certified under Clinical Laboratory Improvement Amendments (CLIA) for high complexity testing. These partnerships enable the actual genetic testing processing for the PGx panel.
• CEimpactcoreStrategic or Co-development PartnerRxGenomix provided support to CEimpact to create the 8-hour ACPE-accredited Pharmacogenomics: A Training for Pharmacists continuing education course. This partnership enables pharmacist training and credentialing for the RxGenomix network.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/rxgenomix
• Facebookfacebook.com/RxGenomix

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RxGenomix